US Patent

US8906851 — Method for treating diabetes

Method of Use · Assigned to Amylin Pharmaceuticals LLC · Expires 2026-08-18 · 0y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Methods for reducing body weight, altering body composition, treating diabetes, and lowering blood glucose levels using exendins or exendin agonists are provided.

USPTO Abstract

Methods for reducing body weight, altering body composition, treating diabetes, reducing HbA 1c and reducing average daily blood glucose by the use of exendins, exendin agonists or exendin analog agonists are provided.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2139 — Farxiga
U-2590 —
U-2588 —
U-2593 —
U-2139 — Farxiga

Patent Metadata

Patent number
US8906851
Jurisdiction
US
Classification
Method of Use
Expires
2026-08-18
Drug substance claim
No
Drug product claim
No
Assignee
Amylin Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.